News Details - novonordisk.com
WEB2 days ago · About Wegovy® (semaglutide 2.4 mg) In the EU, Wegovy ® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m 2 or greater (obesity), or adults with a BMI of 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition ...
News Details - Novo Nordisk
WEBWegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease. Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a supplemental New Drug Application ...
News details - Novo Nordisk
WEBMar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term ...
News details - Novo Nordisk
WEBNov 11, 2023 · Novo Nordisk has filed for a label update of Wegovy ® in the US and EU to include an indication for reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in people with an initial BMI of 27 kg/m 2 or greater and established cardiovascular disease (CVD). A decision is ...
News details - Novo Nordisk
WEBPLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti-obesity medicine for teens with once-weekly dosing.
News Details - Novo Nordisk
WEBJun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity …
WEB1 day ago · Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients. The Danish pharmaceutical giant said late Thursday ...
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
WEBApr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
EU regulator backs use of Novo's Wegovy for obesity-related …
WEB1 day ago · Sept 19 (Reuters) - The European Medicines Agency backed the use of Novo Nordisk's (NOVOb.CO) popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on ...
Wegovy Cuts Risk of Heart Problems, Novo Nordisk Trial Says
WEBAug 8, 2023 · A new obesity drug, Wegovy, slashed the risk of serious heart problems by 20 percent in a large trial, the drug’s maker said on Tuesday, a finding that could challenge the perception of weight...
Skip to content